A best evidence topic was constructed according to a structured protocol. The question addressed was whether radical mediastinal lymphadenectomy should be performed during lung metastasectomy of renal cell carcinoma (RCC). Of the 13 papers found through a report search, seven represent the best evidence to answer this clinical question. The authors, journal, date, country of publication, study type, group studied, relevant outcomes and results of these papers are given. We conclude that on the whole, the seven-retrieved studies support the realization of systematic radical mediastinal lymphadenectomy. The published literature showed a prevalence of lymph node involvement (LNI) that approaches 30%. The majority of the studies conclude that LNI is a significant, independent prognostic of survival. Indeed, some authors did not report any 5-year survival in the case of LNI. On the contrary, however, a 5-year survival of 50% was reported when no LNI was present. To date, the published data do not allow conclusions to be drawn regarding the prognosis of hilar vs mediastinal LNI: only one paper focused on the difference between hilar and mediastinal location and showed no difference. In addition, only one study has compared the survival of patients with or without lymphadenectomy, showing greater survival when mediastinal lymphadenectomy was performed. Despite the poor prognosis of patients with LNI, surgery seems to be the best treatment for potentially curative RCC with metastases. It is known that RCC metastases do not respond well to chemotherapy and radiotherapy. Indeed, reported 5-year survival rate ranged between 3 and 11% for non-operated patients. Consequently, resection must be as complete as possible and include a systematic total mediastinal lymphadenectomy, which will probably yield better loco-regional control and evaluation of prognostic factor. However, the published evidence remains quite limited and mainly based on retrospective studies on highly selected patients, with a low level of evidence. Indeed, most patients referred to surgery are younger, fitter, and have fewer metastases. Consequently, the survival gain could be biased, related more to the resectability and the good performance status rather to the resection itself. Consequently, although these preliminary results are interesting, they must be interpreted with caution.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. The protocol is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You are assessing a 68-year old patient for surgical management of metachronous lung metastases of a renal cell carcinoma (RCC). The chest computed tomography (CT) scan detects two peripheral metastases of 18 and 16 mm in the upper left lobe, with mediastinal nodes in stations 5 and 7, one measuring 12 mm. The positron emission tomography CT shows a hyper-signal on the lesions but not on the mediastinal lymph nodes, and there is also no sign of abdominal recurrence or metastases elsewhere. You decide to perform wedge resections of the two lesions in the upper left lobe. From a radiological point of view, the nodes on the chest CT do not seem suspect. You wonder whether a lymph node sampling would be more appropriate than a radical mediastinal lymphadenectomy (especially due to the risk of injury to the recurrent laryngeal nerve). You, therefore, decide to consult the published evidence concerning the role of mediastinal lymphadenectomy during lung metastasectomy of RCC. 
Continued
SEARCH OUTCOME
A total of 13 papers were identified using the reported search strategy, from which three represented the best evidence to answer the question. Four other articles were found using the references of the selected articles. Papers that were not written in English and that do not provide data on lymphadenectomy during lung metastasectomy of RCC, as well as case reports, were excluded. The seven papers are summarized in Table 1 [2] [3] [4] [5] [6] [7] [8] .
RESULTS
Murthy et al. [2] reported their experience with 92 patients who underwent a lung resection for RCC metastases. Even if the histological data were only available for 35% of the patients, lymph node involvement (LNI) was present in 40% of these patients, with mediastinal involvement in half of the cases. The LNI was a strong prognostic factor of survival (P < 0.01). Indeed, the percentage of survival significantly decreased with the number of lymph nodes affected: 65% in the absence of LNI vs 30% when three nodes were involved, with a median follow-up of 3.7 years. In a smaller study, Kanzaki et al. [3] reported a prevalence of LNI approaching 11%, although the authors had preoperatively attempted to exclude patients suspected of having LNI. However, the authors did not explain which kind of lymphadenectomy was performed (sampling or systematic total lymphadenectomy). In a paper on 105 patients, Plitz et al. [4] reported a 5-year survival rate of 0% when LNI was detected, vs 48% if no LNI was assessed by histology. The multivariate analysis showed that LNI was an independent prognostic factor of survival (P = 0.0016). In a trial performed on 191 patients, Pfannschmidt et al. [5] reported an LNI rate of 30%. This study was in line with the previous papers, illustrating a better survival rate in the absence of LNI (31.4 vs 55.4%; P = 0.0038). This was confirmed by the multivariate analysis, which showed that LNI was an independent prognostic factor of survival (P = 0.0038). However, the authors did not find any differences concerning the mediastinal or hilar nodes involved. Assouad et al. [6] reported their experience with 65 patients, of which 67% had undergone a radical mediastinal lymphadenectomy. The prevalence of LNI was 29.5%, without any difference between hilar and mediastinal nodes. There was no 5-year survival in case of LNI, while more than half of the patients were still alive if no LNI was detected. The multivariate analysis showed LNI as an independent prognostic factor of survival (P = 0.0018). In a retrospective review of 110 patients, Winter et al. [7] reported a prevalence of LNI approaching 35%, with twice as much mediastinal involvement than hilar involvement. They showed, using univariate and multivariate analyses, that LNI was an independent prognostic factor of survival. In addition, they compared these patients to a historical series composed of 111 patients with lung metastases of RCC who did not benefit from a mediastinal lymphadenectomy. Although nonsignificant (P = 0.08), they did find a better rate of survival in the case of lymphadenectomy (hazard ratio (HR): 0.66; CI: 0.41-1.06). In a study based on 202 patients, of whom 45% benefitted from a mediastinal lymphadenectomy, Meimarakis et al. [8] reported a prevalence of LNI of 30%. A significantly lower survival rate was found in the case of LNI (P < 0.001), which was confirmed by the multivariate analysis and which found LNI to be an independent prognostic factor (P < 0.004). 
CLINICAL BOTTOM LINE
Although the low level of evidence of several papers on metastasectomy, including Treasure et al. [9] , prevented the ESTS working group from setting firm recommendations regarding metastasectomy [10] , our work on the role of systematic radical mediastinal lymphadenectomy during lung metastasectomy of RCC clearly makes us in favour of it. Most of the studies show a prevalence of LNI of 30%, with a mediastinal location in half of the cases. Consequently, not performing lymphadenectomy exposes patients to the risk of failing to achieve a complete carcinological resection and loco-regional recurrence. All the papers conclude that LNI is a significant independent prognostic factor of survival. To date, the published data do not allow any conclusion to be drawn regarding the prognostic of hilar vs mediastinal LNI: only one paper focuses on the difference between hilar and mediastinal location, and does not report any difference. In addition, only one study compares the survival of patients with or without lymphadenectomy, and concludes in favour of mediastinal lymphadenectomy. Despite the poor prognosis of patients with LNI, surgery seems to be the best treatment of potentially curative RCC with metastases. It is known that RCC metastases do not respond well to chemotherapy and radiotherapy. Indeed, the reported 5-year survival rate ranged between 3 and 11% for non-operated patients [9] , while it varied from 21 to 60% in most surgical series [11] [12] [13] [14] [15] [16] . Therefore, although consensus has yet to be reached [17] , metastasectomy for lung metastases of RCC seems to be the best treatment for selected patients with resectable disease. Consequently, the resection must be as complete as possible and include a total systematic mediastinal lymphadenectomy (even if imaging is not in favour of such invasion), which will probably yield a better loco-regional control and evaluation of prognostic factor. However, the literature is quite limited and of low-level evidence. In addition, most patients referred for surgery are younger and fitter patients with fewer metastases. Consequently, the survival gain could be biased, related more to the resectability and the good performance status rather to the resection itself [18] . Further studies are necessary to confirm these results.
